-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple system atrophy (MSA) is an adult-onset and sporadic neurological degenerative disease.
Multiple system atrophy (MSA) is an adult-onset and sporadic neurological degenerative disease.
The prognosis of MSA is poor, with a reported median survival time of 6.
Diagnosis In this MSA patient cohort study, the goal is to find survival predictors in clinical and cerebral PET metabolic characteristics.
Survival curve
Early in the course of the disease (average 3 years, IQR 2-5), patients with suspected MSA diagnosed with clinical evaluation and brain PET.
Kaplan-Meier Method to Evaluate the Survival Rate of Patients with Multiple System Atrophy Treated by OH and SSRI
Including 85 patients.
In short, brain PET is a meaningful prognostic assessment, especially in the diagnosis of left insular hypometabolism.
Brain PET is a meaningful prognostic assessment, especially in the diagnosis of hypometabolism in the left insula.
In addition, SSRIs are a potential drug candidate to slow the progression of the disease.
GrimaldiS ,BoucekineM ,WitjasT GrimaldiS Grimaldi BoucekineM Boucekine Witjas T Witjas , et al bmj.
com/content/early/2021/04/22/jnnp-2020-324823" target="_blank" rel="noopener">Early atypical signs and insula hypometabolism predict survival in multiple system atrophy Journal of Neurology, Neurosurgery & Psychiatry Published Online First: 23 April 2021.
Published Online First : doi: 10.
1136/jnnp-2020-324823 doi: leave a message here